Moore Capital Management’s Altimmune ALT Stock Holding History

Moore Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-167	Closed	-$91K	–	410
2014 Q4	$91K	Hold	167	–	–	﹤0.01%	301
2014 Q3	$89K	Buy	+167	New	+$87.3K	﹤0.01%	387

Other funds holding ALT

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Potomac Capital Management New York $115M AUM

Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Moore Capital Management's ALT Position: Q1 2015 in Review

Moore Capital Management sold out of Altimmune (ALT) in Q1 2015, closing a stake of 167 shares — an estimated $91K sold.

Moore Capital Management first reported a position in ALT in Q3 2014 and held it in 2 quarters. The position peaked at $91K in Q4 2014. 36 funds tracked by Wall St. Rank hold ALT as of Q1 2015.

Moore Capital Management reported no remaining Altimmune position as of Q1 2015 after selling out during the quarter.
Moore Capital Management sold 167 Altimmune shares in Q1 2015, an estimated $91K.
Moore Capital Management first reported a position in Altimmune in Q3 2014 and held it in 2 quarters.
Moore Capital Management's Altimmune position peaked at $91K in Q4 2014.
36 funds tracked by Wall St. Rank held Altimmune as of Q1 2015.

Based on Moore Capital Management's 13F filing for Q1 2015, filed 15 May 2015.